EP Patent

EP2576591A2 — Tablet formulation of ezatiostat

Assigned to Telik Inc · Expires 2013-04-10 · 13y expired

What this patent protects

Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.

USPTO Abstract

Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.

Drugs covered by this patent

naloxegol-oxalate (NALOXEGOL OXALATE)

Patent Metadata

Patent number: EP2576591A2
Jurisdiction: EP
Classification: —
Expires: 2013-04-10
Drug substance claim: No
Drug product claim: No
Assignee: Telik Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.